Orphazyme, a late-stage biopharmaceutical company pioneering the heat shock protein response for the treatment of rare diseases, has announced that the phase 3 trial of arimoclomol in ALS did not meet its primary and secondary endpoints to show benefit in people living with ALS. No important safety concerns were detected in the trial. Topline data will be presented at the virtual European Network to Cure ALS (ENCALS) meeting, May 12-14, and complete data from the study will be published later this year. Click here to read Orphazyme press release
